当前位置:药药网 / 数据中心 / 儿科研究特征电子表格
Evotaz tablets
通用名称
atazanavir/cobicistat
儿科标签批准日期
2020/7/31 0:00:00
特定指示/秒
HIV-1 infection in pediatric patients weighing at least 35 kg
标签更改摘要
- Safety and effectiveness for the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg was established through a study with components of EVOTAZ. Use for this indication is supported by evidence from adequate and well-controlled studies in adults, and by pharmacokinetic, safety, and virologic data from an open-label trial of components of Evotaz in pediatric patients with HIV-1 infection aged 12 years and older.
- Safety in these subjects through 48 weeks was similar to that in antiretroviral treatment-naive adults [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.2)].
- Safety and effectiveness in the pediatric population weighing less than 35 kg have not been established. Atazanavir, a component of Evotaz, is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus.
- Information on dosing, adverse reactions, PK parameters, and clinical trial.
- Postmarketing study.
治疗类别
AIDS & AIDS Related Drugs